With PD-1 OK looming, Regeneron antes $100M on bluebird alliance for next-gen TCR cell therapy pact
Sometime in the next few months, we’re likely to see the FDA come through with an approval for the world’s 6th PD-1/L1 checkpoint inhibitor from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
